Neoadjuvant Statistical Algorithm to Predict Individual Risk of Relapse in Patients with Resected Liver Metastases from Colorectal Cancer

Author:

Atienza Ángel Vizcay1ORCID,Iriarte Olast Arrizibita2,Sarrias Oskitz Ruiz2,Lizundia Teresa Zumárraga1,Beristain Onintza Sayar2,Casajús Ana Ezponda3,Gigli Laura Álvarez4,Sastre Fernando Rotellar5,García Ignacio Matos6,Rodríguez Javier Rodríguez1ORCID

Affiliation:

1. Department of Medical Oncology, Clínica Universidad de Navarra, 31008 Pamplona, Spain

2. Department of Mathematics and Statistic, NNBi, 31110 Noain, Spain

3. Department of Radiology, Clínica Universidad de Navarra, 31008 Pamplona, Spain

4. Department of Pathology, Clínica Universidad de Navarra, 31008 Pamplona, Spain

5. Department of HPB Surgery, Clínica Universidad de Navarra, 31008 Pamplona, Spain

6. Department of Medical Oncology, Clínica Universidad de Navarra, 28027 Madrid, Spain

Abstract

(1) Background: Liver metastases (LM) are the leading cause of death in colorectal cancer (CRC) patients. Despite advancements, relapse rates remain high and current prognostic nomograms lack accuracy. Our objective is to develop an interpretable neoadjuvant algorithm based on mathematical models to accurately predict individual risk, ensuring mathematical transparency and auditability. (2) Methods: We retrospectively evaluated 86 CRC patients with LM treated with neoadjuvant systemic therapy followed by complete surgical resection. A comprehensive analysis of 155 individual patient variables was performed. Logistic regression (LR) was utilized to develop the predictive model for relapse risk through significance testing and ANOVA analysis. Due to data limitations, gradient boosting machine (GBM) and synthetic data were also used. (3) Results: The model was based on data from 74 patients (12 were excluded). After a median follow-up of 58 months, 5-year relapse-free survival (RFS) rate was 33% and 5-year overall survival (OS) rate was 60.7%. Fifteen key variables were used to train the GBM model, which showed promising accuracy (0.82), sensitivity (0.59), and specificity (0.96) in predicting relapse. Similar results were obtained when external validation was performed as well. (4) Conclusions: This model offers an alternative for predicting individual relapse risk, aiding in personalized adjuvant therapy and follow-up strategies.

Funder

Government of Navarra’s Department of Economic and Business Development

University of Navarra, Spain

Publisher

MDPI AG

Reference55 articles.

1. Cancer statistics;Siegel;CA Cancer J. Clin.,2022

2. American Cancer Society (2020). Colorectal Cancer Facts & Figures 2020–2022, American Cancer Society.

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA A Cancer, J. Clin.,2021

4. Increasing Incidence of Early-Onset Colorectal Cancer;Sinicrope;N. Engl. J. Med.,2022

5. (2024, July 26). Estimaciones de la Incidencia del Cáncer en España, 2022. Red Española de Registros de Cáncer (REDECAN). Available online: https://redecan.org/storage/documents/873877e1-af1b-43fe-8d97-0ee1434fe261.pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3